Keymed Biosciences Inc. (HKG:2162)
77.75
+0.70 (0.91%)
Aug 20, 2026, 4:09 PM HKT
Keymed Biosciences Revenue
Keymed Biosciences had revenue of 217.56M CNY in the half year ending December 31, 2025, with 706.65% growth. This brings the company's revenue in the last twelve months to 834.63M, down -4.31% year-over-year. In the year 2025, Keymed Biosciences had annual revenue of 716.31M with 67.31% growth.
Revenue (ttm)
834.63M CNY
Revenue Growth
-4.31%
P/S Ratio
23.77
Revenue / Employee
513.62K CNY
Employees
1,625
Market Cap
22.91B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 716.31M | 288.19M | 67.31% |
| Dec 31, 2024 | 428.12M | 74.03M | 20.91% |
| Dec 31, 2023 | 354.10M | 254.03M | 253.87% |
| Dec 31, 2022 | 100.06M | -10.21M | -9.26% |
| Dec 31, 2021 | 110.27M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 19.69B |
| Shanghai Henlius Biotech | 7.42B |
| Zai Lab | 3.53B |
| Shanghai Junshi Biosciences | 3.10B |
| InnoCare Pharma | 2.87B |
| Duality Biotherapeutics | 2.06B |
| HBM Holdings | 1.23B |
| Ascentage Pharma Group International | 638.89M |